Treatment as Prevention
Investment in Research & Development Related to Treatment as Prevention
Since the 2011 publication of the HPTN 052 trial results30 galvanized the field of HIV prevention, treatment as prevention has continued to excite-—and challenge—both research and implementation science. The field reacted enthusiastically in 2012 as treatment as prevention was added to the national strategies of countries and models showed that it could dramatically alter the course of the epidemic. However, the field now confronts the question of how best to implement it programmatically. In this report, the Working Group’s calculation of treatment as prevention investment includes only research that has the primary outcome of decreasing HIV transmission at all CD4 levels (i.e., other health outcomes are included, but research needs to measure transmission and/or incidence impact). Total global investment in treatment as prevention R&D in 2012 was US$98 million, an increase of approximately US$18.6 million from 2011.